ywesee GmbH - the need to Share!

Comment by Philip Hansten on EPha.ch Interactions

Sehr geehrte Damen und Herren

Im folgenden finden Sie den Kommentar von Philip Hansten, bezgl. dem Klassifikationsmodell der EPha.ch Interaktionen.

Reviewer: Philip Hansten
General Comments:
This paper addresses a vitally important issue in the rational use of drug
interaction information in the clinical setting. I believe this paper represents an
important advance in the development of classification systems for drug
interactions for the following reasons:

1. The transparency of the decision model is important. This means that people
working in the field (as well as users) will be able to understand how the
decisions are made, and it should provide a framework for people working in
different centers to communicate effectively. This could be a real advance in the
field of drug interactions.

2. The authors selected appropriate questions for the decision model. They
addressed the factors that are important in the assessment of the clinical
importance of drug interactions in the clinical setting.

3. I ran several drug interactions through their decision model, and I think the
model could be developed into an excellent method for categorizing drug
interactions for the product information. For example, colchicine plus
clarithromycin would be a “DM-E” instead of merely being a strong caution as is
currently the case in the US product information.

Der Artikel in seiner vollen Länge: http://www.biomedcentral.com/imedia/1091625776680024_comment.pdf

Die Interaktionen von EPha.ch sind Public Domain.

http://epha.ch/de/community

Sollten Sie Interesse haben als Gold, Silber oder Bronze Sponsor der EPha-Interaktionen aufzutreten, teilen Sie uns das bitte mit.

Sämtliche Sponsoren der EPha-Interaktionen werden hier erwähnt:

http://download.epha.ch/

Wir arbeiten zur Zeit an den englischen und französischen Übersetzungen der EPha-Interaktionen. Es ist knallharte Gehirn-Arbeit.

Bei Fragen stehen wir gerne zur Verfügung.

MfG
Zeno Davatz
+41 43 540 05 50

PS: Das Profil von Philip Hansten: http://sop.washington.edu/pharmacy/faculty-a-research/philip-hansten.html
PPS: Das LinkedIn Profil von Philip Hansten: http://www.linkedin.com/pub/philip-hansten/26/762/281